Affiliation:
1. Global Pharmaceutical Research Division, Abbott Laboratories, Abbott Park, Illinois 60064
Abstract
ABSTRACT
Restriction enzyme modulation of transformation efficiencies (REMOTE) is a method that makes use of genome restriction maps and experimentally observed differences in transformation efficiencies of genomic DNA restriction digests to discover the location of mutations in genomes. The frequency with which digested genomic DNA from a resistant strain transforms a susceptible strain to resistance is primarily determined by the size of the fragment containing the resistance mutation and the distance of the mutation to the end of the fragment. The positions of restriction enzyme cleavage sites immediately flanking the resistance mutation define these parameters. The mapping procedure involves a process of elimination in which digests that transform with high frequency indicate that the restriction enzyme cleavage sites are relatively far away from the mutation, while digests that transform with low frequency indicate that the sites are close to the mutation. The transformation data are compared computationally to the genome restriction map to identify the regions that best fit the data. Transformations with PCR amplicons encompassing candidate regions identify the resistance locus and enable identification of the mutation. REMOTE was developed using
Haemophilus influenzae
strains with mutations in
gyrA
,
gyrB
, and
rpsE
that confer resistance to ciprofloxacin, novobiocin, and spectinomycin, respectively. We applied REMOTE to identify mutations that confer resistance to two novel antibacterial compounds. The resistance mutations were found in genes that can decrease the intracellular concentration of compounds:
acrB
, which encodes a subunit of the AcrAB-TolC efflux pump; and
fadL
, which encodes a long-chain fatty acid transporter.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference57 articles.
1. Abbanat, D., M. Macielag, and K. Bush. 2003. Novel antibacterial agents for the treatment of serious Gram-positive infections. Expert Opin. Investig. Drugs12:379-399.
2. Mutations in Ribosomal Protein L16 Conferring Reduced Susceptibility to Evernimicin (SCH27899): Implications for Mechanism of Action
3. A Diarylquinoline Drug Active on the ATP Synthase of
Mycobacterium tuberculosis
4. Ausubel, F. M., R. Brent, R. E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith, and K. Struhl (ed.). 1991. Current protocols in molecular biology, p. 2.4.1-2.4.2. John Wiley & Sons, New York, N.Y.
5. Babon, J. J., M. McKenzie, and R. G. Cotton. 2003. The use of resolvases T4 endonuclease VII and T7 endonuclease I in mutation detection. Mol. Biotechnol.23:73-81.
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献